Efficacy and Safety of AEB071 Versus Cyclosporine in de Novo Renal Transplant Recipients

• Status: Completed
• Trial end date: 2012-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess safety and efficacy of AEB071 combined with everolimus in a CNI-free (calcineurin inhibitor) regimen in renal transplant recipients.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Cyclosporine; Cyclosporins; Everolimus; Sirolimus

Criteria

Inclusion criteria:

• Patient has been maintained on study drug for 12 months in the core study

Exclusion criteria:

• Not applicable

• Other protocol-defined inclusion/exclusion criteria may apply